Differences
This shows you the differences between two versions of the page.
| Next revision | Previous revision | ||
| success [2023/07/03 15:34] – created - external edit 127.0.0.1 | success [2024/10/14 00:38] (current) – [Treatments for Migraine] sflitman | ||
|---|---|---|---|
| Line 3: | Line 3: | ||
| We are a clinical research site founded in 2001 by Stephen Flitman, MD, a board-certified neurologist who trained at the Barrow Neurological Institute (Phoenix, Arizona) and completed his fellowship in Cognitive Neuroscience at the prestigious National Institutes of Health (Bethesda, Maryland). He served as first Associate Director then Director of Cognitive Neurology Section at Barrow until 2001. | We are a clinical research site founded in 2001 by Stephen Flitman, MD, a board-certified neurologist who trained at the Barrow Neurological Institute (Phoenix, Arizona) and completed his fellowship in Cognitive Neuroscience at the prestigious National Institutes of Health (Bethesda, Maryland). He served as first Associate Director then Director of Cognitive Neurology Section at Barrow until 2001. | ||
| - | Joshua Tobin, MD joined in 2006 and added expertise in Migraine and atypical headache, leaving after a distinguished career spanning 15 years. | + | Joshua Tobin, MD joined in 2006 and added expertise in Migraine and atypical headache, leaving after a distinguished career spanning 15 years. |
| - | We have been involved in over 200 clinical trials across the gamut of neurological disease and have contributed to the approvals of many drugs. | + | We have been involved in over 250 clinical trials across the gamut of neurological disease and have contributed to the approvals of many drugs. |
| These are the treatments which Xenoscience has helped to develop over the years which were eventually approved by the US Food and Drug Administration (FDA). Most have also been approved by the EU equivalent agency, European Medicines Agency. | These are the treatments which Xenoscience has helped to develop over the years which were eventually approved by the US Food and Drug Administration (FDA). Most have also been approved by the EU equivalent agency, European Medicines Agency. | ||
| Line 16: | Line 16: | ||
| * Exelon | * Exelon | ||
| * Exelon Patch | * Exelon Patch | ||
| + | * Kisunla | ||
| + | * Leqembi | ||
| * Razadyne | * Razadyne | ||
| * Razadyne ER | * Razadyne ER | ||
| Line 32: | Line 34: | ||
| * Cymbalta | * Cymbalta | ||
| + | * Lyrica | ||
| * Savella | * Savella | ||
| Line 38: | Line 41: | ||
| * Emgality | * Emgality | ||
| - | * Pediatric | + | * Maxalt MLT (for children) |
| + | * Qulipta | ||
| * Reyvow | * Reyvow | ||
| * Ubrelvy | * Ubrelvy | ||
| Line 59: | Line 63: | ||
| ===== Treatments for Parkinson' | ===== Treatments for Parkinson' | ||
| - | * Nourianz | + | |
| - | * Stalevo | + | |
| + | * Stalevo | ||
| - | < | + | ===== Closing Thoughts ===== |
| - | < | + | |
| - | < | + | |
| - | < | + | |
| - | < | + | |
| - | < | + | |
| - | </ | + | |
| A sobering thought: | A sobering thought: | ||
